ClinicalTrials.gg
Active, not recruitingNCT06531499RADIODOSEUpdated Oct 20, 2026

A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study

A Phase 1 interventional study of AAA617 and Gonadotropin-releasing hormone (GnRH) analogues in Metastatic Castration-Resistant Prostate Cancer, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 22 sites in 6 countries. Open to male participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

How we know

Updated Oct 20, 2026Now Active, not recruitingPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
110
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms — 21 open to participants now, 31 under way, 2 of them phase 3. lutetium (¹⁷⁷Lu) vipivotide tetraxetan · Prostatic Neoplasms.

Enrollment
11th of 41
110 · median 49
Started
2024
with 7 others
Phase 1
9 of 41
4 open now
Primary completion
2029-04
later than 25 of 30 live
Registered
28th of 41
by date
Lead sponsor
6 of 41
Novartis Pharmaceuticals

Among the 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms, this one is the 11th largest by enrollment, is one of 8 that started in 2024, is one of 9 in phase 1, reaches primary completion later than 25 of the 30 other live ones, and was the 28th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

21 of the 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About lutetium (¹⁷⁷Lu) vipivotide tetraxetan

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 100 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies testing lutetium (¹⁷⁷Lu) vipivotide tetraxetan in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of the study is to assess and evaluate dosimetry, safety, and tolerability following administration of up to 12 cycles of (177Lu) vipivotide tetraxetan (also referred to as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter identified as AAA617) in taxane-naïve adult participants with PSMA-positive mCRPC who progressed on a prior ARPI treatment with normal renal function or mild renal impairment (eGFR ≥ 60ml/min).

Read the detailed description

The study includes screening period, treatment period, and a post-treatment follow-up period.

Screening Period: Approximately 106 participants will be enrolled to receive up to12 consecutive cycles of AAA617. Potential participants will be assessed for eligibility by verifying their baseline PSMA PET scan for mandatory confirmation of PSMA positivity prior to first cycle by local review.

Treatment Period: Eligible participants will be treated with up to 12 cycles of 7.4 GBq AAA617 intravenously every 6 weeks, until radiographic progression, toxicity leading to treatment discontinuation, death, loss to follow-up, or withdrawal of consent, whichever occurs first. During treatment period, all participants who complete the initial 6 cycles of AAA617 treatment will undergo an additional PSMA-PET scan after Cycle 6 to re-assess PSMA expression level and to reassess eligibility of participants to receive additional AAA617 treatment cycles.

Post-Treatment Follow-Up: All participants will undergo a PSMA-PET scan at end of treatment (EOT). The post-treatment follow-up period will consist of EOT; 42-days safety; EOT RLI; safety, survival and rPFS follow-up visits.

The planned duration of treatment period is up to 74 weeks with treatment given every 6 weeks. Participants may be discontinued from treatment earlier due to unacceptable toxicity or disease progression, and/or at the discretion of the Investigator or the participant.

03

Conditions studied

  • Metastatic Castration-Resistant Prostate Cancer

Browse trials for

Keywords

  • Phase 1
  • RADIODOSE
  • AAA617
  • metastatic castration-resistant prostate cancer
  • radiation dosimetry
  • mCRPC
  • Prostate-specific membrane antigen (PSMA)
  • Dosimetry
  • [68Ga]Ga-PSMA-11
  • gallium (68Ga) gozetotide
  • [177Lu]Lu-PSMA-617
  • lutetium (177Lu) vipivotide tetraxetan
  • Radioligand Imaging (RLI)
  • Radioligand Therapy (RLT)
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Signed must be obtained prior to participation in the study.
  • Participants must be adults ≥ 18 years of age.
  • Participants must have an performance status ≤ 1.
  • Participants must have histological confirmation of adenocarcinoma of the prostate.
  • Participants must be PSMA-positive per 68Ga-PSMA PET/CT scans at baseline
  • Participants must have a castrate level of serum/plasma testosterone (\< 50 ng/dL or \< 1.7 nmol/L) either by pharmaceutical or surgical methods.
  • Participants must have progressed only once on prior second generation ARPIs
  • Documented progressive mCRPC
  • Participants must have ≥ 1 lesion by conventional imaging that is present on screening/baseline CT, MRI, or bone scan
  • Renal: ≥ 60 mL/min/1.73m2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
  • Participants must have recovered to ≤ Grade 2 from all toxicities related to prior therapies except alopecia.

Key exclusion Criteria:

  • Previous treatment with any of the following within 6 months of study enrollment: Strontium 89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation
  • Any previous radioligand therapy.
  • Prior treatment with cytotoxic chemotherapy for metastatic castration-resistant or metastatic hormone-sensitive prostate cancer (mHSPC) (e.g., taxanes, platinum, estramustine, vincristine, methotrexate, etc.), immunotherapy or biological therapy [including monoclonal antibodies]. [Note: Taxane exposure (maximum 6 cycles) in the or neoadjuvant setting is allowed if 12 months have elapsed since completion of this adjuvant or neoadjuvant therapy. Prior treatment with sipuleucel-T is allowed].
  • Concurrent therapies: cytotoxic chemotherapy, immunotherapy, radioligand therapy, PARP inhibitor, biological, or therapy
  • History of myocardial infarction (MI), angina pectoris, or coronary artery bypass graft (CABG) within 6 months prior to ICF signature and/or clinically active significant cardiac disease
  • Concurrent serious acute or chronic nephropathy and/or moderate to severe renal impairment as determined by the principal investigator.
  • Diagnosed with other active that are expected to alter or may interfere with disease assessment
  • Sexually active males unwilling to use a condom during intercourse while taking study treatment and for 14 weeks after stopping study treatment.
  • Concurrent urinary outflow obstruction or unmanageable urinary incontinence
  • History of somatic or psychiatric disease/condition that may interfere with the aims and assessments of the study.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
110 participants (actual)

Study arms

  • Experimental
    AAA617

    All participants will receive the investigational product AAA617 (7.4 GBq ±10%).

    Drug: AAA617 · Drug: Gonadotropin-releasing hormone (GnRH) analogues · Drug: Gonadotropin-releasing hormone (GnRH) antagonists

Interventions

06

What researchers measure

Primary outcomes

  1. Time activity curves (TACs) and absorbed radiation dose of AAA617 in organs

    Time activity curve (TAC) will be generated from the amount radioactivity in one given tissue. Time integrated activity coefficient and absorbed dose will be calculated

    Time frame: From Cycle 1 to Cycle 12; cycle = 42 days

  2. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    The distribution of adverse events for Radioligand Therapy (RLT) will be done via the analysis of frequencies for Adverse Event (AEs) and Serious Adverse Event (SAEs) through the monitoring of relevant clinical and laboratory safety parameters. Adverse event monitoring should be continued for at least 42 days following the end of treatment (EOT) visit. Participants receiving the study treatment will continue to be followed for safety every 12 weeks during the long-term follow-up for selected adverse events

    Time frame: For up to 12 cycles in taxane-naive participants with progressive PSMA-positive mCRPC with nrmal kidney function or mild renal impairment; cycle = 42 days

  3. Percentage of participants with AAA617 dose reductions, interruptions and discontinuations

    The assessment of tolerability will be based on the frequency of participants with dose interruptions, reductions, and study treatment discontinuations. Dose reduction will be based on the worst toxicity demonstrated at the last dose.

    Time frame: Up to 42 (+7) days after last AAA617 dose administration (Safety Follow-up)

Secondary outcomes

  1. Time activity curves (TACs) and absorbed radiation dose AAA617 in tumors

    Time activity curves (TACs) will be generated from the amount of radioactivity in one given tissue at a given moment. TACs will be fitted to mono- and bi-exponential curves. Time integrated activity coefficient and absorbed dose will be calculated.

    Time frame: For up to 12 cycles; cycle = 42 days

  2. Pharmacokinetic ( PK) concentration of AAA617 in blood over time

    PK concentrations will be listed by patient and visit/sampling time point. The descriptive summary statistics will be provided by visit/sampling time point.

    Time frame: Cycle 1, Cycle 4, Cycle 6, Cycle 7, Cycle 8, Cycle 9, Cycle 10, Cycle 11 and Cycle 12, cycle = 42 days

  3. Pharmacokinetic (PK) parameter Cmax of AAA617 from blood radioactivity data

    Derived PK parameter, Cmax will be listed by patient and visit. The descriptive summary statistics will be provided by visit. Cmax is the maximum drug concentration after dosing.

    Time frame: Cycle 1, Cycle 4, Cycle 6, Cycle 7, Cycle 8, Cycle 9, Cycle 10, Cycle 11 and Cycle 12; cycle = 42 days

  4. PK parameter Tmax of AAA617 from blood radioactivity data

    Derived PK parameter Tmax, will be listed by patient and visit. The descriptive summary statistics will be provided by visit. Tmax is the time to reach the maximum concentration.

    Time frame: Cycle 1, Cycle 4, Cycle 6, Cycle 7, Cycle 8, Cycle 9, Cycle 10, Cycle 11 and Cycle 12; cycle = 42 days

  5. PK parameter AUC of AAA617 from blood radioactivity data

    Derived PK parameter AUC will be listed by patient and visit. The descriptive summary statistics will be provided by visit. AUC: Area under the concentration-time curve.

    Time frame: Cycle 1, Cycle 4, Cycle 6, Cycle 7, Cycle 8, Cycle 9, Cycle 10, Cycle 11 and Cycle 12; cycle = 42 days

  6. PK parameter CL of AAA617 from blood radioactivity data

    Derived PK parameter CL will be listed by patient and visit. The descriptive summary statistics will be provided by visit. Clearance (CL): Rate at which the body eliminates the drug.

    Time frame: Cycle 1, Cycle 4, Cycle 6, Cycle 7, Cycle 8, Cycle 9, Cycle 10, Cycle 11 and Cycle 12; cycle = 42 days

  7. PK parameter VZ of AAA617 from blood radioactivity data

    Derived PK parameter Vz will be listed by patient and visit. The descriptive summary statistics will be provided by visit. Vz: volume of distribution during the terminal phase (Vz).

    Time frame: Cycle 1, Cycle 4, Cycle 6, Cycle 7, Cycle 8, Cycle 9, Cycle 10, Cycle 11 and Cycle 12; cycle = 42 days

  8. PK parameter terminal T1/2 of AAA617 from blood radioactivity data

    Derived PK parameter terminal T1/2 will be listed by patient and visit. The descriptive summary statistics will be provided by visit. T1/2: Terminal half life.

    Time frame: Cycle 1, Cycle 4, Cycle 6, Cycle 7, Cycle 8, Cycle 9, Cycle 10, Cycle 11, and Cycle 12; cycle = 42 days

  9. Overall response rate (ORR)

    ORR is defined as the proportion of participants with BOR of confirmed CR or PR per investigator assessment and according to Prostate Cancer Working Group 3 (PCWG3) modified-RECIST v1.1.

    Time frame: From first patient first visit (FPFV) to end of study, until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 58 months

  10. Disease Control rate (DCR)

    DCR is defined as the percentage of CR, PR, stable disease or non-CR/non-progressive disease (PD) per investigator assessment and according to PCWG3 modified-RECIST v1.1 assessment in soft tissue, lymph node, and visceral lesions.

    Time frame: From first patient first visit (FPFV) to end of study, until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 58 months

  11. Duration of response (DOR)

    DOR is defined as the duration of time between the date of the first documented BOR (CR or PR) per investigator assessment according to PCWG3 modified-RECIST v1.1 and the date of first documented progression or death due to any cause.

    Time frame: From first patient first visit (FPFV) to end of study, until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 58 months

  12. Radiographic Progressive free survival (rPFS)

    rPFS defined as the time from the date of first dose of study treatment to the date of the first documented radiographic disease progression as assessed by investigator and PCWG3 modified-RECIST v1.1 criteria or death due to any cause, whichever occurs first.

    Time frame: From first patient first visit (FPFV) to end of study, until date of radiographic progression or date of death from any cause, whichever comes first, assessed up to approximately 58 months

  13. Prostate specific antigen (PSA) response

    PSA response is defined as percentage of participants who achieve any decrease from baseline that is confirmed by a second PSA measurement ≥4 weeks. Participants with any decrease in PSA will also be summarized by visit.

    Time frame: Baseline, (Cycle (C), Day (D)) C1D1, C2D1, C3D1, C4D1, C5D1, C6D1, C6D42, C7D1, C8D1, C9D1, C10D1, C11D1, C12D1, End Of Treatment (EOT), 6 weeks after EOT, every 12 weeks after EOT up to 12 months; each cycle = 42 days

  14. Overall survival (OS)

    Overall survival is defined as the time from the first dose of study treatment to death due to any cause.

    Time frame: Cycle 1 to death event, approx. 5 years, (cycle = 42 days)

  15. Duration of exposure to AAA617 and dose intensity

    Duration of exposure: Dose intensity is computed as the ratio of actual cumulative dose received and actual duration of exposure.

    Time frame: during treatment period (74 weeks)

07

Study locations

22 sites
  • University of California LA
    Los Angeles, California 90095, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Wash U School of Medicine
    St Louis, Missouri 63110, United States
  • Nebraska Cancer Specialists
    Omaha, Nebraska 68130, United States
  • Novartis Investigative Site
    Cologne, North Rhine-Westphalia 50937, Germany
  • Novartis Investigative Site
    Wuppertal, North Rhine-Westphalia 42283, Germany
  • Novartis Investigative Site
    Aachen, 52074, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    München, 80377, Germany
  • Novartis Investigative Site
    Rostock, 18057, Germany
  • Novartis Investigative Site
    Nijmegen, 6525 GA, Netherlands
  • Novartis Investigative Site
    Santiago Compostela, A Coruna 15706, Spain
  • Novartis Investigative Site
    Barcelona, 08041, Spain
  • Novartis Investigative Site
    Madrid, 28041, Spain
  • Novartis Investigative Site
    Madrid, 28222, Spain
  • Novartis Investigative Site
    Bellinzona, 6500, Switzerland
  • Novartis Investigative Site
    Bern, 3010, Switzerland
  • Novartis Investigative Site
    Sutton, Surrey SM2 5PT, United Kingdom
  • Novartis Investigative Site
    Birmingham, West Midlands B15 2TH, United Kingdom
  • Novartis Investigative Site
    Glasgow, G12 0YN, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Apr 2029, 53 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 62. This study's planned 53 months is above that.

Counting every sponsor, half of 455 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Nov 2028 → Apr 2029 and completion Nov 2028 → Apr 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2024
First posted
Aug 1, 2024
StartActual
Nov 11, 2024
Primary completionEst.
Apr 24, 2029was Nov 2028
CompletionEst.
Apr 24, 2029was Nov 2028
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 20, 2026
Sites
3 sites added, 2 sites removed
Show 3 added (2 Spain, 1 Netherlands)
  • Novartis Investigative Site · Nijmegen, Netherlands
  • Novartis Investigative Site · Madrid, Spain
  • Novartis Investigative Site · Madrid, Spain
Show 2 removed
  • Novartis Investigative Site · Nijmegen, Netherlands
  • Novartis Investigative Site · Majadahonda, Spain
Oct 20, 2026
Primary completion
Nov 24, 2028→Apr 24, 2029
Oct 20, 2026
Study completion
Nov 24, 2028→Apr 24, 2029
Oct 20, 2026
Enrollment
106 (estimated)→110 (actual)
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Recruiting→Active, not recruiting
    3 sites added, 2 sites removed
    Show 3 added (2 Spain, 1 Netherlands)
    • Novartis Investigative Site · Nijmegen, Netherlands
    • Novartis Investigative Site · Madrid, Spain
    • Novartis Investigative Site · Madrid, Spain
    Show 2 removed
    • Novartis Investigative Site · Nijmegen, Netherlands
    • Novartis Investigative Site · Majadahonda, Spain
    Primary completion Nov 24, 2028→Apr 24, 2029
    Study completion Nov 24, 2028→Apr 24, 2029
    Enrollment 106 (estimated)→110 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06531499
Responsible party
Sponsor
First posted
Aug 1, 2024
Start date
Nov 11, 2024
Primary completion
Apr 24, 2029 (estimated)
Completion
Apr 24, 2029 (estimated)
Last update
Oct 20, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutetium (¹⁷⁷Lu) vipivotide tetraxetan

Start the discussion